Inhibrx (NASDAQ:INBX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.
Valuation & Earnings
This table compares Inhibrx and BioCryst Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Inhibrx | N/A | N/A | N/A | N/A | N/A |
BioCryst Pharmaceuticals | $48.83 million | 40.86 | $-108,900,000.00 | ($0.94) | -11.96 |
Inhibrx has higher earnings, but lower revenue than BioCryst Pharmaceuticals.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Inhibrx and BioCryst Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Inhibrx | 0 | 0 | 4 | 0 | 3.00 |
BioCryst Pharmaceuticals | 0 | 3 | 8 | 0 | 2.73 |
Inhibrx presently has a consensus price target of $34.6667, suggesting a potential upside of 92.27%. BioCryst Pharmaceuticals has a consensus price target of $12.3333, suggesting a potential upside of 9.73%. Given Inhibrx's stronger consensus rating and higher possible upside, research analysts clearly believe Inhibrx is more favorable than BioCryst Pharmaceuticals.
Insider and Institutional Ownership
36.6% of Inhibrx shares are owned by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Inhibrx and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Inhibrx | N/A | N/A | N/A |
BioCryst Pharmaceuticals | -233.45% | -328.70% | -71.11% |
Summary
Inhibrx beats BioCryst Pharmaceuticals on 5 of the 9 factors compared between the two stocks.